Related references
Note: Only part of the references are listed.Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration
Stefano Piermarocchi et al.
ACTA OPHTHALMOLOGICA (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
Meidong Zhu et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2015)
A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs
Christina I. Frennesson et al.
ACTA OPHTHALMOLOGICA (2014)
One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting
Andrea Gabai et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2014)
Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration
Yoko Nomura et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2014)
The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections
Adnan Tufail et al.
OPHTHALMOLOGY (2014)
Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
Allen C. Ho et al.
OPHTHALMOLOGY (2014)
A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study
Sergio Pagliarini et al.
JOURNAL OF OPHTHALMOLOGY (2014)
Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
Randhir Chavan et al.
CLINICAL OPHTHALMOLOGY (2014)
Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany
Robert P. Finger et al.
ACTA OPHTHALMOLOGICA (2013)
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
A. H. Ross et al.
EYE (2013)
Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration
Philipp S. Muether et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2013)
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Brandon G. Busbee et al.
OPHTHALMOLOGY (2013)
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE The LUMIERE Study
Salomon Y. Cohen et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
Wataru Matsumiya et al.
BMC OPHTHALMOLOGY (2013)
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration
Sreekumari Pushpoth et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
Michael W. Stewart
CLINICAL OPHTHALMOLOGY (2012)
Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy
A. Kumar et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2011)
Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12
T. A. Williams et al.
EYE (2011)
Myositis Ossificans
Deborah A. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
Lars Hjelmqvist et al.
JOURNAL OF OPHTHALMOLOGY (2011)
Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2
Prema Abraham et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2010)
The Prevalence of Age-Related Macular Degeneration in Asians A Systematic Review and Meta-Analysis
Ryo Kawasaki et al.
OPHTHALMOLOGY (2010)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
David S. Boyer et al.
OPHTHALMOLOGY (2009)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Improved vision-related function after ranibizumab treatment of Neovascular age-related macular degeneration - Results of a randomized clinical trial
Tom S. Chang et al.
ARCHIVES OF OPHTHALMOLOGY (2007)
Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration
Peter K. Kaiser et al.
OPHTHALMOLOGY (2007)
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration
Anne E. Fung et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
